Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Earnings for AlloVir, Inc. (ALVR)
Earnings in 2023 (TTM): $-190,544,000
According to AlloVir, Inc.'s latest financial reports the company's current earnings (TTM) are $-190,544,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of AlloVir, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-190,544,000 | $-190,418,000 |
| 2022 | $-168,975,000 | $-168,710,000 |
| 2021 | $-170,955,000 | $-171,962,000 |
| 2020 | $-69,784,000 | $-68,381,000 |
| 2019 | $-23,839,000 | $-21,774,000 |
| 2018 | $-2,430,000 | $-2,430,000 |